CASI Pharmaceuticals, Inc. (CASIF) stock
CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.10+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
CASI Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$45.01M. The highest annual figure on record is -$25.08M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.01M | – |
| FY2024 | Dec 31, 2024 | -$39.62M | – |
| FY2023 | Dec 31, 2023 | -$25.08M | – |
| FY2022 | Dec 31, 2022 | -$34.03M | – |
| FY2021 | Dec 31, 2021 | -$41.52M | – |
| FY2020 | Dec 31, 2020 | -$52.78M | – |
See a number that looks wrong?